Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer

European Journal of Cancer Part A

Volumn 33, Issue 4, 1997, Pages 566-574

  Raghavan, D ^a   Koczwara, B ^a   Javle, M ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

chemotherapy; progress; prostate cancer; PSA; therapy; treatment

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTIMETABOLITE; ANTIMITOTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; EPIRUBICIN; ESTRAMUSTINE; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; METHOTREXATE; MITOGUAZONE; MITOMYCIN C; MITOXANTRONE; NAVELBINE; NITROSOUREA DERIVATIVE; PACLITAXEL; PLATINUM DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; TAXANE DERIVATIVE; TOPOTECAN; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ADVANCED CANCER; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CELL CYCLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW;

EID: 0030997896     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00510-2     Document Type: Article

References (101)

1. Jessup MJ, McGinnis LS, Winchester DP, et al. Clinical highlights from the National Cancer Data Base: 1966. CA Cancer J Clin 1996, 46, 185-192.
2. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941, 1, 293-297.
3. Tannock IF. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate. J Clin Oncol 1985, 3, 1013-1021.
4. Raghavan D. Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Semin Oncol 1988, 15, 371-389.
5. Bcgg CB. Methodological issues in studies of the treatment, diagnosis and etiology of prostate cancer. Semin Oncol 1994, 21, 569-579.
6. Dawson NA, McLeod DG. Assessment of response in prostate cancer. Eur J Cancer 1997, 33, 560-565.
7. Horoszewicz JS, Leong SS, Kawinski E, et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983, 43, 1809-1818.
8. Logothetis CJ, Hossein NM, Hsieh JT. The clinical and biological study of androgen independent prostate cancer (AI Pea). Semin Oncol 1994, 21, 620-629.
9. Di Sant'Agnese AP. Neuroendocrine differentiation in carcinoma of the prostate. Cancer 1992, 70, 254-268.
10. Smith DC, Tucker JA, Trump DL. Hypercalcemia and neuroendocrine carcinoma of the prostate. A report of 3 cases and a review of the literature. J Clin Oncol 1992, 10, 499-505.
11. Jelbart ME, Russell PJ, Russell P, Raghavan D. Biology and management of small cell undifferentiated carcinoma of prostate. In Williams CJ, Krikorian J, Green MR, Raghavan D, eds. Textbook of Uncommon Cancer. London, Wiley-Liss, 1988, 249-262.
12. Amato RJ, Logothetis CJ, Hallinan R, Ro JY, Sella A, Dexeus FH. Chemotherapy for small cell carcinoma of prostatic origin. J Urol 1992, 147, 925-937.
13. Traish AM, Wotiz HH. Prostatic epidermal growth factor and their regulation by androgens. Endocrinology 1987, 121, 1461-1467.
14. Kim JH, Sherwood ER, Sutkowski DM, Lee C, Kuzlowski JM. Inhibition of prostatic tumor cell proliferation by suramin: alterations in TGF alpha mediate autocrine growth regulation and cell cycle distribution. J Urol 1991, 146, 171-176.
15. Kyprianou JH, English HF, Isaacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 1990, 50, 3748-3753.
16. Newark JR, Hardy DO, Tomb D, et al. Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci USA 1992, 89, 6319-6323.
17. Hudes GR, Greenberg R, Krigel RI, et al. Phase I study of estramustine and vinblastine, two microtubule inhibitors in hormone-refractory prostate cancer. J Clin Oncol 1992, 10, 1754-1761.
18. Seidman AD, Scher HI, Petrylak D, et al. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial endpoint for hormone-refractory prostatic cancer. J Urol 1992, 147, 931-934.
19. Raghavan D, Cox K, Pearson BS, et al. Oral cyclophosphamide for the management of hormone-refractory prostate cancer. Br J Urol 1993, 72, 625-628.
20. Kelly WK, Scher HI, Mazumdar M. Prostate specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 1993, 11, 607-615.
21. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996, 14, 1756-1764.
22. Sridhara R, Eisenberger MA, Sinibaldi V, Reyno LM, Egorin MJ. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J Clin Oncol 1995, 13, 2944-2953.
23. Slack NH, Mittleman A, Brady MF, et al. The importance of the stable category for chemotherapy treated patients with advanced and relapsing prostate cancer. Cancer 1980, 46, 2393-2402.
24. Yellen SB, Cella DF, Leslie WT. Age and clinical decision making in oncology patients. J Natl Cancer Inst 1994, 86, 1766-1770.
25. Raghavan D, Findlay MPN, McNeil E. Cancer in the elderly. In Peckham MJ, Pinedo H, Veronesi U, eds. Oxford Textbook of Oncology. Oxford, Oxford University Press, 1995, 1439-1450.
26. Yagoda A, Watson RC, Natale RB, et al. A critical analysis of response criteria in patients with prostatic cancer treated with cis-diamminedichloride platinum II. Cancer 1979, 33, 1553-1562.
27. Raghavan D, Pearson B, Coorey G, et al., Management of hormone-resistant prostate cancer: experience at Royal Prince Alfred Hospital. In Johnson DE, Logothetis CJ, Von Eschenbach AC, eds. Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers, 1989, 245-250.
28. Scott WW, Gibbons RP, Johnson DE, et al. Comparison of 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in patients with advanced carcinoma of the prostate. Cancer Chemother Rep 1875, 59, 195-201.
29. Abell F, Wilkes J, Divers L, Huben R, Vellagapudi S, Raghavan D. Oral cyclophosphamide for hormone refractory prostate cancer. Proc Am Soc Clin Oncol 1995, 14, 243 (abstract).
30. Maulard-Durdux C, Dufour B, Hennequin C, Chretien Y, Delanian S, Housset M. Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients. Cancer 1996, 77, 1144-1148.
31. Kyakuno M, Yamaguchi S, Matsumiya K, et al. Intermittent intravenous high dose cyclophosphamide therapy for advanced prostatic cancer with distant metastasis. Hinyokika Kiyo 1989, 35, 1865-1869.
32. Smith DC, Vogelzang NJ, Goldberg HL, et al. High dose cyclophosphamide with granulocyte macrophage colony stimulating factor in hormone refractory prostatic carcinoma. Proc Am Soc Clin Oncol 1992, 11, 213 (abstract).
33. Brandes LJ, Bracken SP, Ramsey EW. N,N-diethyl-2-[4-(phenylmethyl) phenoxy] ethamine in combination with cyclophosphamide: an active, low-toxicity regimen for metastatic hormonally unresponsive prostate cancer. J Clin Oncol 1996, 13, 1398-1403.
34. Mahjoubi M, Azalo M, Ghosh M, et al. Phase II trial of ifosfamide in the treatment of metastatic hormone refractory patients with prostatic cancer. Cancer Invest 1990, 8, 477-481.
35. Saxman S, Ansari R, Drasga R, et al. Phase II trial of cyclophosphamide versus cyclophosphamide, doxorubicin and methotrexate in hormone refractory prostate cancer. Cancer 1991, 15, 2488-2492.
36. Takeuchi S, Fukui I, Higashi Y, et al. Combination chemotherapy with ifosfamide, 5-fluorouracil, cisplatin for stage D2 prostate cancer. Hinyokika Kiyo, Acta Urol (Japan) 1989, 35, 1513-1517.
37. Torti FM, Aston D, Lum BL, et al. Weekly doxorubicin in endocrine refractory carcinoma of the prostate. J Clin Oncol 1983, 1, 477-482.
38. Scher H, Yagoda A, Watson RC, et al. Phase II trial of doxorubicin in bidimensionally measurable prostatic adenocarcinoma. J Urol 1984, 131, 1099-1102.
39. Rangel C, Matzkin H, Soloway MS, et al. Experience with weekly doxorubicin in hormone refractory stage D2 prostate cancer. Urology 1992, 39, 577-582.
40. Ferrari P, Parma A, Villani U, et al. Chemotherapy with epirubicin in hormone unresponse metastatic cancer of the prostate. Eur Urol 1990, 18, 150.
41. Madsen EL, Bastholt L, Bertelsen K, et al. Weekly oral idarubicin in advanced prostatic cancer. A phase II study. Acta Oncol 1992, 31, 337-340.
42. Francini G, Petrioli R, Manganelli A, et al. Weekly chemotherapy in advanced prostatic cancer. Br J Cancer 1993, 67, 1430-1436.
43. Osborne CK, Drelichman A, Von Hoff DD, et al. Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer. Cancer Treat Rep 1983, 67, 1133-1138.
44. Raghavan D, Bishop J, Woods R, Page J, Devine R. Mitoxantrone (ZAN): a non-toxic, moderately active agent for hormone-resistant prostate cancer. Proc Am Soc Clin Oncol 1985, 5, 102 (abstract).
45. Kantoff PW, Bryant P, Block C, et al. 14 day continuous infusion of mitoxantrone HC1 for hormone refractory carcinoma of the prostate. A pilot dose finding study. Proc Am Soc Clin Oncol 1991, 10, 175 (abstract).
46. Reardon TP, Small EJ, Valone F, et al. Phase II trial of mitoxantrone in hormone refractory metastatic prostate cancer. Proc Am Soc Clin Oncol 1992, 11, 218 (abstract).
47. Graf-Dobberstein C, Rubben H, Otto U, et al. Systemic chemotherapy of endocrine resistant prostate carcinoma with cis-platin and mitomycin: final results of a prospective multicenter trial. Eur Urol 1990, 18, 132.
48. Lupera H, Droz JP, Piot G, et al. Phase II trial of combination chemotherapy with fluorouracil, doxorubicin and cis-platin (FAP) in hormonally resistant metastatic prostatic adenocarcinoma. Oncology 1989, 46, 372-374.
49. Trump DL, Marsh JC, Kvols LK, et al. A phase II trial of carboplatin in advanced prostate cancer refractory to hormonal therapy. An Eastern Cooperative Group Pilot Study. Invest New Drugs 1990, 8, 591-594.
50. Bryan C, Munn R, John W, et al. Treatment of hormone refractory stage D prostate carcinoma with CHIP. Proc Am Soc Clin Oncol 1989, 8, 148 (abstract).
51. Slack NH. Results of chemotherapy protocols of the US National Prostatic Cancer Project (NPCP). Clin Oncol 1983, 2, 441-459.
52. Hansen R, Moyrihan T, Beatty P, et al. Continuous systemic 5FU infusion in refractory prostatic cancer. Urology 1991, 37, 358-361.
53. De Wys WD, Begg CB, Brodovsky H, et al. A comparative clinical trial of adriamycin and 5-fluorouracil in advanced prostatic cancer: prognostic factors and response. The Prostate 1983, 4, 1-11.
54. Koch P, Bayer G, McGovern J, et al. Continuous infusion of 5-fluorouracil and weekly doxorubicin for hormone resistant prostate cancer. Proc Am Soc Clin Oncol 1992, 11, 207 (abstract).
55. Blumenstein B, Crawford ED, Saiers JH, et al. Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate. A Southwest Oncology Group study. J Urol 1993, 150, 411-413.
56. Hussain M, Kish JA, Ensley JF, et al. Evaluation of 5-FU and cisplatin based combination chemotherapy in the treatment of patients with D2 hormone refractory adenocarcinoma of the prostate. Proc Am Soc Clin Oncol 1991, 10, 176 (abstract).
57. Kasimis BS, Miller JB, Kaneshiro CA, et al. Cyclophosphamide v 5-fluorouracil, doxorubicin, and mitomycin C (FAM) in the treatment of hormone-resistant metastatic carcinoma of the prostate: a preliminary report of a randomized trial. J Clin Oncol 1985, 5, 385-392.
58. Loening SA, Beckley S, Brady MF, et al. Comparison of estramustine phosphate, methotrexate, and cis-platinum in patients with advanced, hormone refractory prostate cancer. J Urol 1983, 129, 1001-1006.
59. Soloway MS, DeKernion JB, Gibbons RP, et al. Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced hormone refractory, previously irradiated carcinoma of the prostate. J Urol 1981, 125, 664-667.
60. Dexeus F, Logothetis CJ, Samuels ML, et al. Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer. Cancer Treat Rep 1985, 69, 885-886.
61. Jones WG, Fossa SD, Denis L, et al. An EORTC phase II study of vindesine in advanced prostate cancer. Eur J Cancer Clin Oncol 1983, 19, 583-588.
62. Burris H III, Fields S, Wilding G, et al. Navelbine, an active agent in the treatment of hormone refractory prostate cancer. Cancer Invest 1995, 13, 45-46.
63. Hartley-Asp B. Estramustine-induced mitotic arrest in two human prostatic carcinoma cell lines DU-145 and PC-3. The Prostate 1984, 5, 93-100.
64. Benson RC. Estramustine phosphate: clinical experience in the United States. In Uro-Oncology Update, Experimental and Therapeutic Progress in Prostate Cancer. New York, Promedicine Communications, 1988, 19-22.
65. Rosenthal MA, Grygiel J, Raghavan D, et al. The treatment of disseminated prostate cancer with estramustine. Aust NZ J Surg 1992, 62, 871-873.
66. Soloway MS, Beckley S, Brady MF, et al. A comparison of estramustine phosphate versus cisplatinum in patients with advanced hormone refractory prostate cancer who had had extensive irradiation to pelvis or lumbosacral area. J Urol 1983, 127, 56-61.
67. Pienta K, Redman B, Hussain M, et al. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 1994, 12, 2005-2012.
68. Speicher LA, Barone L, Tew KD. Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res 1992, 52, 4433-4440.
69. Reese D, Burris H, Belledegrun A, et al. A phase I/II study of navelbine (vinorelbine) and estramustine in the treatment of hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 1996, 15, 259 (abstract).
70. Scher HI, Curley T, Yeh S, et al. Therapeutic alternatives in hormone refractory prostatic cancer. Semin Urol 1992, 10, 55-64.
71. Tejada F, Eisenberger MA, Broder LA, et al. 5-fluorouracil v CCNU in the treatment of metastatic prostatic cancer. Cancer Treat Rep 1977, 61, 1589-1590.
72. Loening SA, Scott WW, deKernion J, et al. A comparison of hydroxyurea, methyl-chloroethyl-cyclohexyl-nitrosourea and cyclophosphamide in patients with advanced carcinoma of the prostate. J Urol 1981, 125, 812-816.
73. Page JP, Levi JA, Woods RL, et al. Randomized trial of combination chemotherapy in hormone-resistant metastatic prostatic carcinoma. Cancer Treat Rep 1985, 69, 105-107.
74. Giantonio BJ, Kosierowski R, Ramsey HE, et al. Phase II study of topotecan for hormone refractory prostate cancer. Proc Am Soc Clin Oncol 1993, 12, 247 (abstract).
75. Emerson DL, Vuong A, MacIntyre MS, Besterman JM. In vivo efficacy of two camptothecin analogs in the human cancer xenograft model. Proc Am Soc Clin Oncol 1993, 34, 419 (abstract).
76. Roth B, Yeap B, Wilding G, et al. Taxol in advanced hormone refractory prostate cancer: an ECOG phase II trial. Proc Am Soc Clin Oncol 1992, 11, 196 (abstract).
77. Scher HI, Yagoda A, Ahmed T, et al. Methyl-glyoxal-bis(guanyl)hydrazone in hormone-resistant adenocarcinoma of the prostate. J Clin Oncol 1985, 3, 224-228.
78. Moore MR, Graham SD, Birch R, et al. Phase II evaluation of mitoguazone in metastatic hormone-resistant prostate cancer: a Southeastern Cancer Study Group trial. Cancer Treat Rep 1987, 71, 89-90.
79. Nguyen NM, Lehr JE, Pienta KJ. Pentosan inhibits angiogenesis in vitro and suppresses prostate tumor growth in vivo. Anticancer Res 1993, 13, 2143-2148.
80. Vukanovic J, Passiniti A, Hirata T, Traytsman RJ, Hartley-Asp B, Isaacs JT. Antiangiogenic effects of the quinoloine 3 carboxamide linomide. Cancer Res 1993, 53, 1833-1837.
81. Vukanovic J, Hartley-Asp B, Issacs JT. Inhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancers. The Prostate 1995, 26, 235-246.
82. Bang Y-J, Kim S-J, Danielpour D, et al. Cyclic AMP induces transforming growth factor-β2 gene expression and growth arrest in the human androgen-independent prostate carcinoma cell line PC-3. Proc Am Acad Sci USA 1992, 89, 3556-3560.
83. Fang W-G, Pirnia F, Bang Y-J, et al. P2-purinergic receptor agonists inhibit the growth of androgen-independent prostate carcinoma cells. J Clin Invest 1992, 89, 191-196.
84. Pietrzkowski Z, Mulholland G, Gomella L, et al. Inhibition of growth of human prostatic cancer cell lines by peptide analogues of insulin-like growth factors. Cancer Res 1993, 53, 1102-1106.
85. Sklar GN, Eddy HA, Jacobs SC, et al. Combined antitumor effect of suramin plus irradiation in human prostate cancer cells: the role of apoptosis. J Urol 1993, 150, 1526-1532.
86. Igawa M, Tanabe T, Chodak GW, Rukstalis DB. N-(4-hydroxyphenyl) retinamide induces cell cycle specific growth inhibition in PC3 cells. The Prostate 1994, 24, 299-305.
87. Thibault A, Cooper MR, Figg WD, et al. A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res 1994, 54, 1690-1694.
88. Raghavan D. Adjuvant systemic therapy of prostate cancer. Semin Oncol 1996, 22, 633-640.
89. Pilepich MV, Sause WT, Shipley WU, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcionma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995, 45, 616-623.
90. Goldenberg SL, Klotz LH, Srigley J, et al. Randomized, prospective, controlled study comparing radical prostatecomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. J Urol 1996, 156, 873-877.
91. Schmidt JD. Cooperative clinical trials of the National Prostatic Cancer Project: protocol 900. The Prostate 1994, 5, 387-399.
92. Schmidt JD, Gibbons RP, Murphy GP, et al. Adjuvant therapy for localized prostate cancer. Cancer 1993, 71, 1005-1013.
93. Yamada AH, Lieskovsky G, Petrovich Z, et al. Results of radical prostatectomy and adjuvant therapy in the management of locally advanced, clinical stage TC, prostate cancer. Am J Clin Oncol 1994, 17, 277-285.
94. Hanks GE, Hanlon AL, Hudes G, et al. Patterns of failure analysis of patients with high pretreatment prostate specific antigen levels treated by radiation therapy: the need for improved systemic and locoregional treatment. J Clin Oncol 1996, 14, 1093-1096.
95. Seifter EJ, Bunn PA, Cohen MH, et al. A trial of combination chemotherapy followed by hormonal therapy for previously untreated metastatic carcinoma of the prostate. J Clin Oncol 1986, 4, 1365-1373.
96. Citrin DL, Hogan TF, Davis TE. Chemohormonal therapy of metastatic prostate cancer. A pilot study. Cancer 1983, 52, 410-414.
97. Eisenkraft S, Huben RP, Pontes JE. Orchiectomy and chemotherapy with estramustine, cis-platinum, cyclophosphamide, and 5-fluorouracil in newly diagnosed prostate cancer with bone metastases. Urol 1984, 23 (Suppl.), 51-53.
98. Osborne CK, Blumenstein B, Crawford ED, et al. Combined versus sequential chemo-endocrine therapy in advanced prostate cancer. Final results of a Southwest Oncology Group Study. J Clin Oncol 1990, 8, 1675-1682.
99. Scher HI, Logothetis CJ. Chemotherapy of hormone refractory prostate cancer. In Raghavan D, Scher HI, Leibel SA, Lange PH, eds. Principles and Practice of Genitourinary Oncology. Philadelphia, Lippincott-Raven, 1996, 599-612.
100. Esrig D, Freeman JA, Elmajian DA, et al. Transitional cell carcinoma involving the prostate with a proposed staging classification for stromal invasion. J Urol 1996, 156, 1071-1076.
101. Loehrer PJ, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992, 10, 1066-1072.